Skip to main content

Voyager Therapeutics enters agreement with AbbVie

Voyager Therapeutics Inc. (Nasdaq: VYGR) entered an exclusive strategic collaboration and option agreement with AbbVie Inc. (NYSE: ABBV) to develop and commercialize vectorized antibodies to treat Alzheimer's disease. Shares of Voyager Therapeutics leaped $4.30 to close at $23.66 while AbbVie stock slipped 62 cents to close at $117.98.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.